The cost of Alzheimer’s
Executive Summary
The Congressional Budget Office estimates that the Alzheimer's Breakthrough Act of 2007 would authorize the appropriation of $24 million in fiscal year 2008 with an estimated $3.9 billion in total appropriations expected through 2012. The Act, sponsored by Sens. Barbara Mikulski, D-Md., and Kit Bond, R-Mo., would provide more funds for disease research, public education and an Alzheimer's call center, as well as state demonstration projects. Though no legislative action is planned for the bill, FDA plans to hold an Oct. meeting with neurology organizations to discuss drug treatments and biomarker developments for the disease (1"The Pink Sheet" Aug. 13, 2007, p. 10)...
You may also be interested in...
FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting
Drug treatments and biomarker development for Alzheimer's disease are on the agenda of a meeting FDA expects to hold in October with neurology organizations, Janet Woodcock, the agency's chief medical officer, said during a July 25 audio conference sponsored by Avalere
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.